<?xml version="1.0" ?>
<document id="6858a81e65c28599c9e674b9b8aa77ab11b79fad">
  <chunk id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c0" text="3D Structure Prediction of Human β1- Adrenergic Receptor via Threading-Based Homology Modeling for Implications in Structure-Based Drug Designing">
    <entity charOffset="131-135" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c0.e0" ontology_id="CHEBI_23888" text="Drug" type="chemical"/>
  </chunk>
  <chunk id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1" text="Dilated cardiomyopathy is a disease of left ventricular dysfunction accompanied by impairment of the β 1 -adrenergic receptor (β 1 -AR) signal cascade. The disturbed β 1 -AR function may be based on an elevated sympathetic tone observed in patients with heart failure. Prolonged adrenergic stimulation may induce metabolic and electrophysiological disturbances in the myocardium, resulting in tachyarrhythmia that leads to the development of heart failure in human and sudden death. Hence, β 1 -AR is considered as a promising drug target but attempts to develop effective and specific drug against this tempting pharmaceutical target is slowed down due to the lack of 3D structure of Homo sapiens β 1 -AR (hsβADR1). This study encompasses elucidation of 3D structural and physicochemical properties of hsβADR1 via threading-based homology modeling. Furthermore, the docking performance of several docking programs including Surflex-Dock, FRED, and GOLD were validated by re-docking and cross-docking experiments. GOLD and Surflex-Dock performed best in re-docking and cross docking experiments, respectively. Consequently, Surflex-Dock was used to predict the binding modes of four hsβADR1 agonists. This study provides clear understanding of hsβADR1 structure and its binding mechanism, thus help in providing the remedial solutions of cardiovascular, effective treatment of asthma and other diseases caused by malfunctioning of the target protein.">
    <entity charOffset="527-531" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e0" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="586-590" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e1" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="613-627" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e2" ontology_id="CHEBI_52217" text="pharmaceutical" type="chemical"/>
    <entity charOffset="949-953" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e3" ontology_id="CHEBI_29287" text="GOLD" type="chemical"/>
    <entity charOffset="1014-1018" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e4" ontology_id="CHEBI_29287" text="GOLD" type="chemical"/>
    <pair e1="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e0" e2="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e2" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.p0" relation="true"/>
    <pair e1="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e0" e2="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e3" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.p1" relation="true"/>
    <pair e1="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e0" e2="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e4" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.p2" relation="true"/>
    <pair e1="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e1" e2="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e2" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.p3" relation="true"/>
    <pair e1="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e1" e2="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e3" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.p4" relation="true"/>
    <pair e1="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e1" e2="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e4" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.p5" relation="true"/>
    <pair e1="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e2" e2="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e3" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.p6" relation="true"/>
    <pair e1="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e2" e2="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.e4" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c1.p7" relation="true"/>
  </chunk>
  <chunk id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2" text="The sequence of hsβADR1 (AC No: P08588) was retrieved from UniProt KB [30]. This target sequence comprises of 477 amino acid residues was submitted to NCBI-Protein BLAST [31] to Fig 1. Schematics of strategy implemented towards successful homology modeling of hsβADR1 and its docking studies. *Y00 = Dobutamine, P32 = Cyanopindolol, P0G = Nanobody (Nb35), CAU = Carazolol, ERC = FAUC50. RET = Retinal, P32 = Cyanopindolol, CAU = Carazolol, Y00 = Dobutamine, WHJ = Carmoterol, 5FW = Isoprenaline, 68H = Salbutamol, TIM = Timolol, JRZ = ICI 118,551.">
    <entity charOffset="114-119" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2.e0" ontology_id="CHEBI_46882" text="amino" type="chemical"/>
    <entity charOffset="114-124" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2.e1" ontology_id="CHEBI_33704" text="amino acid" type="chemical"/>
    <entity charOffset="120-124" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2.e2" ontology_id="CHEBI_37527" text="acid" type="chemical"/>
    <pair e1="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2.e0" e2="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2.e1" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2.p0" relation="true"/>
    <pair e1="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2.e0" e2="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2.e2" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2.p1" relation="true"/>
    <pair e1="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2.e1" e2="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2.e2" id="6858a81e65c28599c9e674b9b8aa77ab11b79fad.c2.p2" relation="true"/>
  </chunk>
</document>
